“Demonstrating comparative value is foundational to meet the clinical, financial, and operational goals in delivering health and care. I integrate work across digital health, payers, health systems, and the life sciences to deploy the strategy that translates value into differentiated models for care delivery, payment, and contracting.”
David J. Wierz is a Senior Advisor with Discern Health. His expertise delivers revenue models and business roadmaps for products and services that build sustainable returns in care management, digital health, and life sciences for early-stage to Fortune 50 companies for US and global markets.
David’s leadership focuses on execution. He builds evidence that demonstrates comparative clinical, financial, and operational gains across providers, manufacturers, payers, and consumers. David applies his knowledge of how policy defines payment and care delivery to create business operations and systems that enhance the management of patients in post-acute and long-term care. Central to his work is improving the ability for organizations to meet the inked goals for refining clinical outcomes, together with building consumer engagement and financial performance.
Prior to joining Discern, David led US, North American and global operations, setting commercial value and payment strategies in life sciences (Lifescan, Pfizer, Takada, Baxalta, Novartis Oncology), digital health (Symptom Control, Biosign, Life Navigator) and care delivery (TakeCare, SSM Health) organizations. He currently serves as a Health and Digital Health Due Diligence Reviewer and Portfolio Advisor for Ben Franklin Technology Partners (BFTP) of Southeastern Pennsylvania.
Areas of Expertise
- Go-to-market strategy, value & payment
- Integrated care models – post-acute, at-home, chronic
- Performance-based analytics & contracting
- iMSA – University of Illinois – In Process
- MA (ABD) – Wharton Doctoral Program, The University of Pennsylvania
- AB – The College, The University of Chicago
Honors and Awards
- Incite Award – Biosimilar Franchise Evaluation – Baxalta